Asset Details
Do you wish to reserve the book?
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
Do you wish to request the book?
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
2019
Overview
Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and describes three major types: epithelioid, sarcomatoid and biphasic, a combination of the former two types. Molecular profiling studies have not addressed intra-tumor heterogeneity in MPM to date. Here, we use a deconvolution approach and show that molecular gradients shed new light on the intra-tumor heterogeneity of MPM, leading to a reconsideration of MPM molecular classifications. We show that each tumor can be decomposed as a combination of epithelioid-like and sarcomatoid-like components whose proportions are highly associated with the prognosis. Moreover, we show that this more subtle way of characterizing MPM heterogeneity provides a better understanding of the underlying oncogenic pathways and the related epigenetic regulation and immune and stromal contexts. We discuss the implications of these findings for guiding therapeutic strategies, particularly immunotherapies and targeted therapies.
Malignant pleural mesothelioma (MPM) is a rare and aggressive form of cancer. Here, the authors show MPM is heterogeneously composed of epithelioid and sarcomatoid components and their proportions associate with prognosis and could inform therapeutic strategies.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/51
/ 45/88
/ 49/22
/ 49/39
/ 49/61
/ 49/90
/ 631/114
/ 631/337
/ 631/67
/ 692/4028
/ 82/79
/ Adult
/ Aged
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Cancer
/ Epigenesis, Genetic - drug effects
/ Female
/ Genetic Heterogeneity - drug effects
/ Humanities and Social Sciences
/ Humans
/ Lung Neoplasms - drug therapy
/ Male
/ Pleural Neoplasms - drug therapy
/ Pleural Neoplasms - genetics
/ Pleural Neoplasms - immunology
/ Pleural Neoplasms - pathology
/ Pulmonology and respiratory tract
/ Science
/ Tumors
